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We identiﬁed in a cohort of patients with frontotemporal dementia (n = 481) or amyotrophic lateral sclerosis (n = 147), 10 index
patients carrying a TBK1 loss of function mutation reducing TBK1 expression by 50%. Here, we describe the clinical and
pathological characteristics of the 10 index patients and six of their affected relatives carrying a TBK1 mutation. Six TBK1 carriers
were diagnosed with frontotemporal dementia, seven with amyotrophic lateral sclerosis, one with both clinical phenotypes and two
with dementia unspeciﬁed. The mean age at onset of all 16 TBK1 carriers was 62.1  8.9 years (range 41–73) with a mean disease
duration of 4.7  4.5 years (range 1–13). TBK1 carriers with amyotrophic lateral sclerosis had shorter disease duration than
carriers with frontotemporal dementia. Six of seven TBK1 carriers were diagnosed with the behavioural variant of frontotemporal
dementia, presenting predominantly as disinhibition. Memory loss was an important associated symptom in the initial phase of the
disease in all but one of the carriers with frontotemporal dementia. Three of the patients with amyotrophic lateral sclerosis
exhibited pronounced upper motor neuron symptoms. Overall, neuroimaging displayed widespread atrophy, both symmetric
and asymmetric. Brain perfusion single-photon emission computed tomography or ﬂuorodeoxyglucose-positron emission tomog-
raphy showed asymmetric and predominantly frontotemporal involvement. Neuropathology in two patients demonstrated TDP-43
type B pathology. Further, we compared genotype–phenotype data of TBK1 carriers with frontotemporal dementia (n = 7), with
those of frontotemporal dementia patients with a C9orf72 repeat expansion (n = 65) or a GRN mutation (n = 52) and with
frontotemporal dementia patients (n = 259) negative for mutations in currently known causal genes. TBK1 carriers with fronto-
temporal dementia had a later age at onset (63.3 years) than C9orf72 carriers (54.3 years) (P = 0.019). In clear contrast with TBK1
carriers, GRN carriers were more often diagnosed with the language variant than the behavioural variant, and presented in case of
the diagnosis of behavioural variant, more often than TBK1 carriers with apathy as the predominant characteristic (P = 0.004).
Also, TBK1 carriers exhibited more often extrapyramidal symptoms than C9orf72 carriers (P = 0.038). In conclusion, our study
identiﬁed clinical differences between the TBK1, C9orf72 and GRN carriers, which allows us to formulate guidelines for genetic
diagnosis. After a negative result for C9orf72, patients with both frontotemporal dementia and amyotrophic lateral sclerosis should
be tested ﬁrst for mutations in TBK1. Speciﬁcally in frontotemporal dementia patients with early memory difﬁculties, a relatively
late age at onset or extrapyramidal symptoms, screening for TBK1 mutations should be considered.
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Introduction
Frontotemporal lobar degeneration (FTLD) is a term cover-
ing a heterogeneous group of neurodegenerative disorders
with predominant atrophy of the frontal and/or the tem-
poral lobes of the brain. It is the third most common form
of dementia after Alzheimer’s disease and vascular demen-
tia, and accounts for 5–10% of all dementia patients
(Prince et al., 2014). In individuals younger than 65
years, it is the second most common cause of dementia
after Alzheimer’s disease.
FTLD is remarkably heterogeneous in clinical presenta-
tion, neuropathological characteristics and underlying gen-
etic causes. Clinically, frontotemporal dementia (FTD) is
characterized by a progressive deterioration in behaviour,
personality and/or language with relative preservation of
memory function. It can be divided in two clinical subtypes:
a behavioural variant, and a language variant or primary
progressive aphasia (PPA). PPA can be further subdivided
into progressive non-ﬂuent aphasia, semantic dementia and
logopenic progressive aphasia, although the latter is fre-
quently associated with underlying atypical Alzheimer’s dis-
ease pathology (Gorno-Tempini et al., 2011).
Pathologically, FTLD is divided in different subclasses ac-
cording to the major inclusion protein that is found in pro-
tein depositions in degenerating neurons: TAR DNA
binding protein 43 (TDP-43, encoded by TARDBP;
FTLD-TDP), microtubule associated protein tau (MAPT,
FTLD-tau), FUS RNA binding protein (FUS, FTLD-FUS)
or no inclusions (FTLD-ni) (Mackenzie et al., 2010).
Clinical and population-based studies showed that FTD is
familial in 30–50% of patients, with an autosomal domin-
ant inheritance in up to 40% (Goldman et al., 2005).
About 17–40% of Mendelian inherited forms of FTD are
explained by a mutation in GRN, MAPT or C9orf72 and
more rarely by a mutation in VCP or CHMP2B (Sieben
et al., 2012).
About 15% of patients with FTD also develop amyo-
trophic lateral sclerosis (ALS), a motor neuron disease
clinically characterized by progressive muscle weakness,
muscular atrophy, fasciculations and spasticity (Lomen-
Hoerth et al., 2002). Also common neuropathological
ﬁndings and genetic causes suggest that FTD and ALS
are two extremes of a continuum of neurodegenerative
disorders. Both ALS and FTD have pathological sub-
groups characterized by inclusions of the TDP-43 or
FUS proteins (van Langenhove et al., 2012). Genetically,
C9orf72 repeat expansions are the most common cause of
FTD and ALS, explaining 25% of familial FTD and 37%
of familial ALS patients (Majounie et al., 2012). Up to
88% of familial patients with FTD and ALS (FTD-ALS)
are explained by the C9orf72 repeat expansion (Cruts
et al., 2013).
Most recently, TANK-binding kinase 1 (TBK1) was iden-
tiﬁed as a gene for ALS and FTD in which loss of function
mutations result in 50% loss of TBK1 protein (Cirulli et al.,
2015; Freischmidt et al., 2015; Gijselinck et al., 2015a;
Pottier et al., 2015). TBK1 is an important serine/threonine
kinase of the IB kinase family. It phosphorylates a wide
range of substrates, including optineurin (OPTN) (Gleason
et al., 2011; Weidberg and Elazar, 2011) and p62
(SQSTM1), two proteins involved in autophagy and asso-
ciated with FTD and ALS (Maruyama et al., 2010; Fecto
et al., 2011; Rubino et al., 2012; van der Zee et al., 2014).
These ﬁndings emphasized once more a major role of de-
fective autophagy in neurodegeneration (Mizushima et al.,
2008).
We sequenced the coding sequence of TBK1 in a Belgian
cohort of 481 unrelated FTD and FTD-ALS patients, and
147 ALS patients, and identiﬁed 10 patients carrying a
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loss of function mutation. The overall TBK1 loss of func-
tion mutation frequency in the Belgian FTD and ALS
patient cohort was 1.7%, of which 1.1% in FTD, 4.5%
in FTD-ALS and 3.4% in ALS patients. This made TBK1
loss of function mutations the third most frequent cause of
FTD and the second most frequent cause of ALS in the
Belgian patient cohorts (Gijselinck et al., 2015a). One loss
of function mutation, p.Glu643del, segregated in an
extended FTD-ALS family, DR158 (Fig. 1A). In two
TBK1 carriers, brain and spinal cord was investigated
and the pathological diagnosis was TDP type B
(Gijselinck et al., 2015a). Here, we describe the clinical
characteristics of TBK1 carriers with FTD or ALS. We
also compared the genotype–phenotype data of FTD
patients with a TBK1 mutation with those of FTD patients
with a causal mutation in GRN or C9orf72, two other
genes implicated in FTLD TDP-43 (Sieben et al., 2012),
and those of 259 patients with FTD without identiﬁed
mutations. With the current study we aimed to discover
speciﬁc clinical characteristics which can suggest the pre-
sence of a TBK1 mutation. In particular for patients with
(a familial history of) both FTD and ALS, speciﬁc clinical
characteristics could help in a clinically based differenti-
ation with C9orf72 carriers.
Materials and methods
Patients and relatives
The FTD, FTD-ALS and ALS patients were part of larger
cohorts recruited since 1998 by neurologists of different uni-
versity and general hospitals nationwide, collaborating in the
framework of the Belgian Neurology (BELNEU) consortium.
Index patients were evaluated using a standard protocol,
which included a detailed clinical and family history, clinical
neurological examination, neuropsychological testing, bio-
chemical analyses, and neuroimaging. The diagnosis of pos-
sible or probable FTD was made according to the
international consensus criteria (Gorno-Tempini et al., 2011;
Rascovsky et al., 2011). Patients with a combination of the
behavioural and the language variant of FTD at presentation
were denoted as mixed FTD. Diagnosis of FTD-ALS was made
in patients with FTD who also met the criteria for clinical
possible or probable ALS according to the revised El Escorial
criteria (Brooks et al., 2000; de Carvalho et al., 2008).
Autopsy and neuropathological examinations had been per-
formed for two TBK1 carriers. Additional relatives of muta-
tion carriers for whom detailed neurological records were
available were included in the current study. All data records,
medical records, neuroimaging studies, and autopsy reports
were reviewed, and the demographic, clinical and pathological
characteristics of each patient were summarized in a standar-
dized format. Among relatives of Family DR158, segregating
the TBK1 p.Glu643del mutation, there were two affected rela-
tives of the index patient with FTD-ALS who were diagnosed
with dementia unspeciﬁed (Gijselinck et al., 2015a). These pa-
tients with unspeciﬁed dementia were combined with the
group of FTD/FTD-ALS patients in the clinical studies of
TBK1. More detailed information on the clinical evaluation
and technical investigations can be found in the
Supplementary material.
For molecular genetic studies, index patients and their
relatives were contacted by trained research nurses.
Detailed information on family history of dementia and/or
ALS was gathered, and additional patients and unaffected
family members were asked to participate in genetic studies.
A positive family history was deﬁned as the occurrence of at
least one affected relative with dementia or motor neuron
disease. Criteria for autosomal dominant inheritance were
deﬁned as the occurrence of at least three affected indi-
viduals with dementia or motor neuron disease in the
pedigree in two or more generations. Written informed con-
sent for participation in the clinical and genetic studies, and
for brain autopsy when appropriate, was obtained from par-
ticipants and/or from their legal guardians. The clinical
study protocol and the informed consent forms for patient
ascertainment were approved by the local ethics committees
of each of the collaborating neurological centres. The gen-
etic and pathological study protocols and informed consent
forms were approved by the Ethics committee of the
University Hospital of Antwerp and the University of
Antwerp, Belgium.
Molecular genetic analysis
The coding region of TBK1 was sequenced using massive
parallel sequencing as described in the Supplementary mater-
ial and in Gijselinck et al. (2015a). All carriers of a repeat
expansion mutation in C9orf72 or a loss of function muta-
tion in GRN (Cruts et al., 2006), were included in the current
genotype–phenotype correlation study performed in the
Belgian FTD and FTD-ALS cohort. C9orf72 repeat expansion
testing was performed by repeat-primed PCR, as described
(Gijselinck et al., 2012). GRN loss of function mutations
were detected using Sanger sequencing or next-generation
sequencing. Data of affected relatives of index patients were
included if they or their offspring carried the mutation. The
genetic and clinical characteristics of the C9orf72 and GRN
carriers are summarized in Supplementary Table 1. The
mutation-negative FTD patients (n = 259) were analysed for
mutations in GRN, C9orf72, MAPT and VCP, as well as for
10 other Mendelian genes associated with other major neu-
rodegenerative brain diseases, i.e. Alzheimer’s disease, prion
disease, ALS and Parkinson’s disease (APP, PSEN1, PSEN2,
PRNP, TARDBP, FUS, SOD1, LRRK2, PARK2, SNCA).
The genetic proﬁling of the known genes was performed by
use of a next-generation sequencing gene panel based on
high-level multiplex PCR ampliﬁcation of targeted exons
using the Multiplex Ampliﬁcation of Speciﬁc Targets for
Resequencing (MASTR) technology (www.multiplicom.com),
followed by sequencing on a MiSeq platform (Illumina). The
non-mutation carriers in this paper were also negative for the
C9orf72 repeat expansion and TBK1 loss of function
mutations.
Statistical analysis
Average onset age and average disease duration were com-
pared between ALS and FTD patients carrying a TBK1 muta-
tion, using a Mann-Whitney U-test because of the small
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Figure 1 Families segregating the TBK1mutation p.Glu643del. (A) DR158 pedigree; (B) DR663 pedigree. To protect the privacy of the
family members, the gender of each person was masked, the order of sibs was scrambled and the number (n) of tested at-risk individuals shown in
white diamonds was not specified. Filled symbols are clinically affected patients with their age at onset (AAO) in years (y) below the symbol. Age
at death (AAD) is shown for individuals who died at old age without symptoms. Age at last evaluation (AALE) is shown for currently unaffected
mutation carriers that are still alive. An asterisk identifies the family members of whom genomic DNA was available and a ‘c’ identifies the TBK1
p.Glu643del mutation carriers. A ‘ + ’ sign indicates which DR663 members are carriers of the C9orf72 repeat expansion. The arrow identifies the
proband of the family. Only the clinically affected patients known to carry the mutation and of whom clinical records were available, were
described in this paper. Other family members pictured as clinically affected were not described because the clinically affected state was only
based on oral information obtained from relatives or because their mutation status was not known. (C) Liability risk curve for TBK1 loss of
function (LOF) mutation carriers. This curve shows the proportion (%) of TBK1 loss of function mutation carriers (y-axis) that is affected at a
certain age (years) (x-axis). The crosses stand for censoring of the patients that are clinically still unaffected at the last time of clinical evaluation or
at death. The crosses are placed on the curve at the age of last evaluation or at the age of death.
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sample group. Comparison of average onset age and average
disease duration between carriers of a mutation in one of the
three genes (TBK1, C9orf72 or GRN), or non-mutation car-
riers, was performed using the non-parametric Kruskal Wallis
test and Mann-Whitney U-test because onset age and disease
duration were not normally distributed in all groups (Shapiro-
Wilk test) and because of the small group of TBK1 mutation
carriers. Clinical characteristics were compared using a Fisher
exact test. All tests were two-tailed and the level of signiﬁcance
was set at P5 0.05.
Results
Demographic characteristics
Demographic, genetic and clinical data of all TBK1 carriers
diagnosed with FTD, FTD-ALS or ALS are summarized in
Table 1. The mean age at onset of TBK1 carriers was
62.1  8.9 years (range 41–73) with a mean disease dur-
ation of 4.7  4.5 years (range 1–13). Three TBK1 carriers
also had a C9orf72 repeat expansion: Patient DR1044 and
two members of Family DR663 (Fig. 1B and Table 1).
When excluding these three double mutation carriers, the
mean onset age of TBK1 carriers was 64.5  6.7 years
(range 48–73) and the mean disease duration 5.7  4.8
years (range 1–13). Patients with ALS, including the three
C9orf72 carriers, had an earlier mean age at onset
(58.1  9.4 years) than patients with FTD (65.5  8.0
years) and a shorter mean disease duration (1.7  1.0
years and 7.1  4.8 years, respectively), almost reaching
the level of signiﬁcance (P = 0.054 and P = 0.052,
respectively). However, when we excluded the three
C9orf72 repeat expansion carriers, the difference in onset
age was much smaller (65.5  8.0 years in FTD versus
63.0  4.5 years in ALS) (P = 0.214). The disease duration
was still much shorter in ALS patients than FTD patients
(1.6  1.3 years and 7.1  4.8 years’ respectively), but not
signiﬁcantly (P = 0.143).
A liability risk curve based on onset age or age at last
clinical evaluation of TBK1 carriers and relatives (n = 34;
18 affected, 16 unaffected), showed that 50% of the TBK1
carriers were affected by the age of 70 (Fig. 1C). Conversely,
four TBK1 carriers were still unaffected at ages of 73, 79, 81
and 82 years. Six carriers were members of the same family,
Family DR158, in which the TBK1 mutation, p.Glu643del,
co-segregates with disease (Gijselinck et al., 2015a) (Fig. 1A).
In Families DR158 and DR663 (Fig. 1B), the segregation
pattern was compatible with autosomal dominant inheritance.
Further, four index patients had at least one affected relative
with dementia or motor neuron disease, but the criteria we
used for autosomal dominant inheritance were not met. Three
index patients did not have a documented familial history of
neurodegenerative diseases, and for one index patient we had
no information.
Behavioural, language and cognitive
dysfunction
Of the TBK1 carriers, ﬁve had behavioural variant FTD,
one PPA, one behavioural variant FTD plus ALS and two
unspeciﬁed dementia. Details on their behavioural,
Table 1 Genetic, demographic and clinical data of TBK1 loss of function mutation carriers
TBK1 mutation Patients/
relativesa
Gender Familial
history
Age at
onset, y
Age at
death, y
Disease
duration,
years
Clinical
diagnosis
Diagnosis
subtype
p.Glu643del c.1927_1929delGAA DR158 III.1 Male F-AD 69 72 3 ALS Spinal onset
III.2 Male F-AD 69 75 6 FTD BvFTD
III.3 Male F-AD 70 73 3 D
III.6 Female F-AD 61 74 13 FTD BvFTD
III.8b Female F-AD 62 74 11 FTD-ALS BvFTD, spinal onset
III.9 Female F-AD 73 84 11 D
DR467 Female F 64 4 9 FTD BvFTD
DR663 II.1c Male F-AD 51 53 2 ALS Bulbar onset
II.2b,c Male F-AD 41 41 5 1 ALS Bulbar onset
DR1044c Male S 63 66 3 ALS Unknown
DR1121 Male F 70 4 6 FTD PPA
DR1122 Female S 69 4 7 FTD BvFTD
p.Gly272_Thr331del c.992 + 1G4T DR189d Male F 48 50 2 FTD BvFTD
p.Ser398Profs*11 c.1192delT DR1123 Male F 59 4 5 ALS Bulbar onset
p.Ser518Leufs*32 c.1551_1552insTT DR1124d Female U 64 64 5 1 ALS Bulbar onset
p.Asp167del c.499_501delGAT DR1127 Male S 60 61 1 ALS Unknown
aRoman numbers indicate affected relatives in Families DR158 and DR663 (Fig. 1).
bPatient III.8 is the proband of Family DR158, Patient II.2 of Family DR663.
cCarriers of a C9orf72 repeat expansion mutation.
dPatients with a pathological diagnosis of TDP-43 proteinopathy.
D = dementia unspecified; F = familial; F-AD = familial-autosomal dominant; S = sporadic.
cDNA is numbering based on NM_013254.3.
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cognitive, and clinical characteristics are shown in Table 2.
In the patients with behavioural variant FTD, behavioural
disinhibition and social inappropriate behaviour was pre-
sent in more patients than apathy, especially in the early
disease stage. However, some patients such as Patients
DR189 and III.2 in Family DR158, presented concomi-
tantly with apathy or passivity as well as elements of dis-
inhibition such as aggressiveness and inappropriate
laughing. Aggressive behaviour and motor agitation with
runaway behaviour were frequent in TBK1 carriers. Also
echolalia and perseverations were quite common in these
patients. Visual hallucinations were present in one patient
of Family DR158 (Patient III.6).
PPA Patient DR1121 had a clinical picture characterized by
an important reduction in spontaneous speech with severe
difﬁculties in word retrieval. No clear comprehension prob-
lems were reported in hetero-anamnesis, although he scored
0/3 on the ACE-R (Addenbrooke’s Cognitive Examination-
Revised) word comprehension test. He produced some seman-
tic paraphasias. No oral apraxia was present. The patient
became more apathetic and passive, and developed severe
problems in short-term memory. Five other patients with
behavioural variant FTD or patients with unspeciﬁed demen-
tia also suffered from word retrieval difﬁculties. Furthermore,
one behavioural variant FTD carrier, Patient DR1122, exhib-
ited impaired repeating of function words as well as an
important reduction of spontaneous speech later in the evo-
lution of the disease. This last feature was also present in two
patients of Family DR158: the patient with FTD-ALS (Patient
III.8) and a patient with unspeciﬁed dementia (Patient III.9).
This latter patient was also known to have alcoholism.
Initially, this patient had especially anterograde memory
deﬁcits as well as mild visuoconstructive apraxia. A clinical
diagnosis of Korsakoff dementia was considered. During
follow-up, the patient developed a more global cognitive
deterioration with deﬁcits in short-term memory, executive
dysfunctions and behavioural disturbances including apathy
and hyperorality. As the patient initially presented with
early prominent memory difﬁculties, the criteria for FTD
(Rascovsky et al., 2011) were not met, although the clinical
evolution was suggestive of FTD. The alcohol abuse can be
considered as an early behavioural change that might have
been related to FTD as it only occurred during the 5 years
before disease onset. The other patient in Family DR158 with
unspeciﬁed dementia (Patient III.3) was previously (at the age
of 47) diagnosed with multiple sclerosis. The ﬁrst reported
cognitive problems consisted of progressive short-term
memory problems, disorientation, apathy and episodes of
confusion. These cognitive problems were attributed to
further progression of multiple sclerosis and no detailed
neuropsychological examination was performed.
Memory and encoding difﬁculties were remarkably pre-
sent in TBK1 carriers: seven of eight patients with FTD or
unspeciﬁed dementia, one patient with ALS and the
FTD-ALS patient, had complaints of episodic memory loss
relatively early in the disease. Also disorientation in time
and/or space was present in ﬁve patients. Because of the T
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occurrence of an early amnestic syndrome, one patient,
Patient DR1122, received initially a diagnosis of amnestic
mild cognitive impairment, and another patient (Patient
III.2) in Family DR158, was diagnosed with Alzheimer’s
disease. In this last patient, doubt persisted in the differential
diagnosis between the frontal variant of Alzheimer’s disease
and FTD. However, all patients with FTD also developed
important behavioural problems early in the disease.
One patient, Patient DR1124, who was eventually diag-
nosed with bulbar ALS, presented initially with memory
problems and a score of 24/30 on MMSE (Mini-Mental
State Examination). The patient also exhibited signs of be-
havioural disinhibition and impulsivity. However, this pa-
tient soon developed a rapidly progressive form of bulbar
ALS that overruled the cognitive symptoms and no further
diagnostic workup was performed concerning cognition.
Psychiatric symptoms were present in seven TBK1 car-
riers: six of nine patients with FTD, FTD-ALS or unspeci-
ﬁed dementia and one ALS patient. Six of these patients
were members of Family DR158. In this family, we
observed a very high load of psychiatric diseases (relapsing
depressions, alcohol abuse, bipolarity and schizophrenia) in
TBK1 carriers as well as non-mutation carriers.
Motor neuron disease and
extrapyramidal symptoms
Seven TBK1 carriers had a diagnosis of pure ALS and one a
diagnosis of co-occurring ALS and FTD. Four ALS patients
had a bulbar onset and two a spinal onset, and of two we
had no records or information on the site of onset. We had
detailed clinical information of ﬁve ALS patients. The index
patient of the Family DR158 (Patient III.8) presented with
initial symptoms of progressive gait problems, aggressive
behaviour and reduced spontaneous speech. Signs of upper
motor neuron disease as hyperreﬂexia and spasticity,
especially of the right leg and the left arm, were most prom-
inent at presentation. The re-evaluation 7 years post-diagno-
sis, in which the patient had not been followed by a
neurologist, revealed a totally mute patient, bed-ridden in de-
corticate posture with gastrostomy tube. Further, Patients
DR1123 and DR1124 had most prominent upper motor
neuron signs. Patient DR1123 initially presented with
bulbar dysarthria, and later, progressive gait disturbances ap-
peared and ﬁne motor skills decreased. One and a half years
after disease onset, he developed important respiratory weak-
ness with need for BiPAP (bilevel positive airway pressure)
and dysphagia with placement of PEG (percutaneous endo-
scopic gastrostomy). Discrete muscle atrophy was present.
After 3.5 years he had developed quadriparesis with spasticity
and hyperreﬂexia. Patient DR1124 developed severe bulbar
speech with important bulbar affect lability, over a period of
8 weeks. Discrete atrophy of the tongue with fasciculations
was present. The patient was diagnosed with a rapidly pro-
gressive ALS and developed a spastic quadriparesis over a
period of only 3 months. In contrast, Patient II.1 of Family
DR663 did not present with any pyramidal signs. His ﬁrst
complaints consisted of dysarthria and dysphagia. First, the
diagnosis of myasthenia gravis was assumed and a beneﬁciary
effect of pyridostigmine treatment on the dysphagia was
noted. During follow-up, the patient developed slight limb
muscle atrophy. Patient III.1 of Family DR158 had clear
upper motor neuron as well as lower motor neuron signs.
The patient presented with gait disturbances, balance prob-
lems and extrapyramidal symptoms (poker face, hypokinesia
and positional tremor). Subsequently, he rapidly developed
limb paresis, fasciculations, muscle atrophy and hyperreﬂexia.
One patient with FTD (Patient III.6) of Family DR158
displayed hypertonia of the left hemicorpus with Babinski
sign on the left side and a central left facial nerve paresis.
These clinical symptoms were hypothesized to be related to
the pronounced right frontal lobe atrophy on brain MRI.
Patient III.3 of Family DR158 had a diagnosis of multiple
sclerosis since the age of 47. He exhibited paresis of the
lower limbs with spasticity, hyperreﬂexia and Babinski
signs, which were attributed to his diagnosis of secondary
progressive multiple sclerosis. Later in the disease he devel-
oped paresis and spasticity of the upper limbs as well.
In four patients with FTD and one patient with ALS,
extrapyramidal symptoms were reported. In all FTD
patients rigidity was present, one also exhibited bradykine-
sia and another, a resting tremor. The patient with ALS
presented with positional tremor and bradykinesia. All
patients with extrapyramidal symptoms were carriers of
the TBK1 p.Glu643del mutation.
Technical investigation findings
Records of performed structural imaging were available for
all TBK1 carriers with a clinical diagnosis of FTD or FTD-
ALS, two patients with unspeciﬁed dementia and two pa-
tients with ALS (Table 3). Various patterns of atrophy were
observed on visual inspection. When atrophy was localized,
the temporal region was most frequently involved.
Asymmetric atrophy was seen in ﬁve patients. In four, the
right hemisphere was more severely affected than the left
hemisphere. On the MRI images in Patient III.3 of Family
DR158, demyelinating lesions were present at the semioval
centre, in the periventricular regions and infratentorial at
the level of the brainstem, compatible with his diagnosis of
multiple sclerosis.
Functional imaging was performed in three TBK1 car-
riers with a FTD diagnosis, consisting of single-photon
emission computed tomography (SPECT) in one patient
and PET with 18F-ﬂuorodeoxyglucose (FDG-PET) in two
patients. In all, predominant hypoperfusion or glucose
hypometabolism was seen in the frontal and temporal re-
gions. The parietal regions were also involved, but to a
lesser extent. Also, in all, the pattern of hypoperfusion or
glucose hypometabolism was asymmetric. In two patients,
the left side was more severely affected and in one patient
the right side. FDG-PET images of the two patients with
predominant left side involvement (Patients DR1121 and
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DR1122) are illustrated in Fig. 2. Both patients displayed a
similar pattern of frontal, anterior and medial temporal
and, to a lesser extent, parietal hypometabolism.
However, the pattern was less extended in Patient
DR1121, who was clinically diagnosed with PPA. The
other patient, Patient DR1122, clinically diagnosed with
behavioural variant FTD, also exhibited language difﬁcul-
ties such as word retrieval difﬁculties, impaired repeating
and loss of spontaneous speech. In Patient DR1122, amyl-
oid PET imaging was also performed, which was not com-
patible with Alzheimer’s disease. Lumbar puncture with
evaluation of the levels of b-amyloid, total tau and phos-
pho-tau181P in CSF was performed in three TBK1 carriers
with FTD. In all three, the CSF biomarkers proﬁle was not
compatible with Alzheimer’s disease. In one, there was an
isolated increased total tau.
We had detailed information on EMG investigations in
ﬁve TBK1 carriers with ALS. In three, chronic denervation
signs such as giant potentials and reduced interference pat-
terns were reported. In one, active denervation signs and
fasciculations were also observed. Remarkably, EMG in
Patients DR1123 and DR1124 did not show obvious
neurogenic changes, compatible with their clinical presen-
tation of predominantly upper motor neuron signs.
Neuropathology
The clinical diagnosis of FTD was autopsy-conﬁrmed in one
TBK1 carrier, Patient DR189. Macroscopically, there was a
mild atrophy of the frontal cortices and to a lesser extent of
the temporal neocortex (Fig. 3A). Furthermore, mild hippo-
campal atrophy was present. Microscopically, a moderate
number of TDP-43 neuronal cytoplasmic inclusions and
short dystrophic neurites were detected throughout all
layers of the frontal and temporal neocortices, in the hippo-
campal dentate gyrus, the parahippocampal transentorhinal
cortex, the neostriatum and the pallidum [Fig. 3B(i and ii)].
No neuronal intranuclear inclusions were observed. In the
internal capsule, a moderate amount of glial cytoplasmic
inclusions were present. These lesions stained positive for
p62 [Fig. 3B(iv and v)], and to a lesser extent for ubiquitin.
These ﬁndings were compatible with FTLD TDP type B
proteinopathy (Mackenzie et al., 2011).
In Patient DR1124, the diagnosis of ALS was autopsy-
conﬁrmed. Macroscopically, mild cortical frontal and mild
hippocampal atrophy was noted. Pathological signs of lower
motor neuron disease were present, manifesting as neuronal
loss in the hypoglossal nucleus as well as in the ventral
horns of the cervical and thoracic spinal cord.
Additionally, loss of Betz cells and severe demyelination of
the pyramidal tract in mesencephalon, pons, medulla oblon-
gata and the entire spinal cord conﬁrmed the presence of
upper motor neuron disease. The TDP-43- and p62-positive
neuronal cytoplasmic inclusions were mainly restricted to the
lower motor neurons, i.e. the hypoglossal nucleus and the
ventral horn neurons of cervical and thoraco-lumbar spinal
cord [Fig. 3B(iii–vi)]. The ﬁndings of TDP-43 staining in the
cortex were most suggestive for TDP type B proteinopathy.
Besides the TDP-43 pathology, a moderate amount of AT8-
immunoreactive tufted astrocytes and ‘neuroﬁbrillary
tangle’-like neuronal cytoplasmic inclusions was found in
the frontal and temporal neocortex (Fig. 3C). More technical
details on the performed neuropathological investigations
can be found in the Supplementary material.
Table 3 Imaging findings in TBK1 carriers
Patients/
relativesa
Structural imaging Functional imaging
(FDG PET/SPECT)
Localization atrophy Symmetry Localization
hypometabolism/
hypoperfusion
Symmetry
DR158 III.1 No clear atrophy
III.2 H, O4G (incl. C) R4 L
III.3 FR BI
III.6 T4G (incl. C) (T) R4 L
III.8b T, C (T) R4 L
III.9 G BI
DR467 H, T (T) R4 L
DR663 II.1c
DR1121 FR, T4G L4R FR, T4 P L4R
DR1122 No clear atrophy FR, T4 P L4R
DR189d T4 FR, P BI FR, T, P (FR, P) BI
R4 L (T)
DR1123
DR1124d T, H BI
aRoman numbers indicate affected relatives in Families DR158 and DR663 (Fig. 1).
bPatient III.8 is the proband of Family DR158 .
cCarrier of a C9orf72 repeat expansion mutation.
dPatients with a neuropathological diagnosis of TDP-43 proteinopathy.
BI = bilateral; C = cerebellar; FDG = fluorodeoxyglucose; FR = frontal; G = global; H = hippocampal; L = left; O = occipital; P = parietal; R = right; SPECT = single-photon emission
computed tomography; T = temporal.
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Genotype–phenotype correlations in
patients with FTD
Demographic and clinical data of the seven TBK1 carriers
with FTD were compared to 65 C9orf72 carriers, 52 GRN
carriers and 259 non-mutation carriers (Table 4). The mean
onset age in the TBK1 carriers was 63.3  7.7 years,
whereas C9orf72 carriers were signiﬁcantly younger at
disease onset (54.3  9.2 years, P = 0.019) (Fig. 4A).
When only taking into account the index patients, the sig-
niﬁcance remained (P = 0.049). The mean disease duration
of TBK1 carriers was relatively long (8.2  4.9 years), but
not signiﬁcantly different than that of the other patient
groups.
Of the seven TBK1 carriers with FTD, one was also
diagnosed with ALS (14.3%). ALS was so far not reported
Figure 2 Neuroimaging using FDG-PET. These images are z-map renderings of the FDG-PET in Patients DR1121 and DR1122. The z-maps
are calculated by comparing the individual glucose metabolic pattern to the normal age-matched control. Both imaging series show a similar
pattern of remarkable asymmetry with a severely decreased metabolism in the left frontal, and anterior and medial temporal lobe. These results
are much more asymmetric than age could explain, do not follow typical age-related patterns, and are much more intense.
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Figure 3 Neuropathology. (A) Macroscopy Patient DR189. Macroscopic picture of the right cerebral and cerebellar hemisphere of Patient
DR189, from a lateral view (i) and a medial view (ii). (B) TDP-43 and p62 immunohistochemistry. Staining for TDP-43 and p62 of the frontal
cortex (i and iv) and the hippocampus (ii and v) of FTLD Patient DR189 and for the spinal cord of ALS Patient DR1124 (iii and vi). TDP-43 and
p62 positive neuronal cytoplasmic inclusions are indicated with an arrow. (C) AT8 staining of the hippocampus and parahippocampal gyrus
DR1124. AT8 staining showed many neuronal cytoplasmic inclusions in the dentate gyrus of the hippocampus (i). In the parahippocampal cortex,
neuronal neurofibrillary tangles or neuronal cytoplasmic inclusions were found (arrow, ii), whereas in the white matter, glial astrocytic cytoplasmic
inclusions (arrowhead, iii and iv) and tufted astrocytes (double arrow, iv) were present.
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in any FTD patient with a GRN mutation. C9orf72 car-
riers had the highest proportion of FTD-ALS patients with
23.1%. This was a signiﬁcantly higher proportion than in
familial non-mutation FTD patients (1.3%, P5 0.001),
sporadic non-mutation FTD patients (4.9%, P = 0.001)
and non-mutation FTD patients with unknown familial his-
tory (3.7%, P = 0.001). Similar results were obtained when
only including the index patients (P5 0.001, P = 0.002 and
P = 0.001, respectively). One of seven TBK1 carriers was
diagnosed with PPA, which was a similar proportion as in
FTD patients caused by a C9orf72 repeat expansion
(14.3% versus 13.1%). The GRN carriers were the only
patient group in which there was a higher proportion of
PPA diagnoses in comparison to behavioural variant FTD
diagnoses (47.6% PPA versus 45.2% behavioural variant
FTD). GRN carriers presented signiﬁcantly more often with
PPA (mostly progressive non-ﬂuent aphasia) compared to
C9orf72 carriers (13.1%, P50.001) and sporadic
non-mutation carriers (23.9%, P = 0.009). In the index
patients-only analysis, there was only a signiﬁcant differ-
ence in proportion of PPA patients between GRN carriers
(7/16, 43.8%) and C9orf72 carriers (7/47, 14.9%)
(P = 0.033).
Behavioural disinhibition and social inappropriate behav-
iour was more frequent than apathy in TBK1 carriers with
behavioural variant FTD (83.3% and 16.7%, respectively).
This is in contrast with GRN carriers who present signiﬁ-
cantly more often with apathy as the most prominent be-
havioural characteristic (87.5%, P = 0.004) (Fig. 4B). In the
behavioural variant FTD index patients-only analysis,
75.0% (3/4) of the TBK1 carriers had behavioural disin-
hibition and social inappropriate behaviour as most prom-
inent behavioural feature in comparison with only 16.7%
(1/6) of the GRN carriers, although comparative analysis
did not reveal signiﬁcant differences (P = 0.190). TBK1 car-
riers presented often with extrapyramidal symptoms
(57.1%), which was signiﬁcantly more often than
C9orf72 carriers (17.6%, P = 0.038) and borderline signiﬁ-
cantly more often than GRN carriers (18.9%, P = 0.054)
(Fig. 4C). In the index patients-only analysis, signiﬁcance
was reached for TBK1 index carriers (3/5, 60.0%) in com-
parison with GRN carriers (1/14, 7.1%) (P = 0.037), but
lost for TBK1 carriers in comparison with C9orf72 carriers
(8/42, 19.0%) (P = 0.076). A high incidence of psychiatric
symptoms such as psychosis, depression and substance
abuse, was observed in TBK1 carriers (57.1%). In all
Table 4 Demographic and clinical characteristics of TBK1 carriers versus C9orf72, GRN or non-mutation carriers
TBK1 C9orf72 GRN No mutation
Familial Sporadic Unknown
FTD patients (index), n 7 (5) 65 (51) 52 (21) 76 (76) 102 (102) 81 (81)
Male, n (%) 3 (42.9) 36 (55.4) 23 (44.2) 44 (57.9) 57 (55.9) 48 (59.3)
Age at onset, y Mean (SD) 63.3 (7.7) 54.3 (9.2) 61.0 (6.5) 63.9 (9.2) 61.7 (11.0) 68.5 (11.4)
Median (range) 64 (48–70) 54 (29–75) 62 (45–70) 65 (29–79) 63 (29–83) 72 (42–82)
Disease duration, y Mean (SD) 8.2 (4.9) 6.0 (4.8) 5.6 (2.1) 6.0 (3.14) 7.1 (4.2) 8.8 (3.0)
Median (range) 8.7 (2–13) 4.7 (1–19) 5.4 (2–11) 6.0 (1–14) 7.0 (1–22) 9.0 (5–12)
Familial history, n (%) F-AD 3 (42.9) 35 (53.8) 18 (34.6) 15 (19.7)
F 3 (42.9) 21 (32.3) 16 (30.8) 61 (80.3)
S 1 (14.3) 3 (4.6) 5 (9.6) 102 (100.0)
U 0 6 (9.2) 13 (25.0) 81 (100.0)
Clinical subtype, n (%*) BvFTD 6 (85.7) 51 (83.6) 19 (45.2) 41 (63.1) 62 (67.4) 19 (65.5)
PNFA 0 5 (8.2) 16 (38.1) 5 (7.7) 13 (14.1) 4 (13.8)
SD 1 (14.3) 3 (4.9) 4 (9.5) 14 (21.5) 7 (7.6) 4 (13.8)
LA 0 0 0 0 2 (2.2) 0
PPA U 0 0 0 1 (1.5) 0 0
Mixed FTD 0 2 (3.3) 3 (7.1) 4 (6.2) 8 (8.7) 2 (6.9)
Behavioural subtype, n (%*) Apathetic 1 (16.7) 14 (31.1) 14 (87.5) 13 (36.1) 25 (41.7) 6 (66.7)
Disinhibition 5 (83.3) 31 (68.9) 2 (12.5) 23 (63.9) 35 (58.3) 3 (33.3)
FTD-ALS , n (%*) Total 1 (14.3) 15 (23.1) 0 1 (1.3) 5 (4.9) 3 (3.7)
Bulbar onset 0 3 (4.6) 0 0 1 (1.0) 1 (1.2)
Spinal onset 1 (14.3) 3 (4.6) 0 1 (1.3) 0 0
Bulbospinal onset 0 5 (7.7) 0 0 3 (2.9) 0
Unknown onset 0 4 (6.2) 0 0 1 (1.0) 2 (2.5)
Extrapyramidal symptoms, n (%*) 4 (57.1) 9 (17.6) 7 (18.9) 22 (33.3) 24 (27.9) 10 (37.0)
Psychiatric symptoms, n (%*) Total 4 (57.1) 16 (30.7) 7 (18.9) 15 (24.6) 28 (33.3) 5 (25.0)
Psychosis 2 (28.6) 8 (15.3) 2 (5.4) 4 (6.6) 12 (14.3) 2 (10.0)
Depression 2 (28.6) 7 (13.4) 5 (13.5) 7 (11.5) 14 (16.7) 3 (15.0)
Abuse 0 4 (7.7) 0 4 (6.6) 4 (4.8) 1 (5.0)
BvFTD = behavioural variant of FTD; F = familial; F-AD = familial-autosomal dominant; LA = logopenic progressive aphasia; PNFA = progressive non-fluent aphasia; PPA U = primary
progressive aphasia unspecified subtype; S = sporadic; SD = standard deviation ; U = unknown.
*Percentage (%) within group of patients for whom we have information.
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other patient groups, the proportion of patients with psy-
chiatric symptoms was smaller, but in comparative analyses
no signiﬁcance was reached, although a borderline result
was obtained in comparison with GRN carriers (18.9%)
(P = 0.054) (Fig. 4D). In the index patients-only analysis,
a smaller proportion of TBK1 carriers had psychiatric
symptoms (2/5, 40.0%), which was not signiﬁcantly more
than in any other group.
Discussion
Loss of function mutations in TBK1 are the third most
frequent cause of clinical FTD after C9orf72 and GRN in
the Belgian patient cohort, and the second most frequent
cause of clinical ALS after C9orf72 (Gijselinck et al.,
2015a). Here, we described the detailed clinical character-
istics of 16 TBK1 carriers, of which six were clinically
diagnosed with FTD, seven with ALS, one with FTD-ALS
and two with unspeciﬁed dementia. Also, we provided the
results of the genotype–phenotype characteristics of TBK1
carriers compared to those of C9orf72 and GRN carriers,
and non-mutation carriers with FTD.
The age at onset of TBK1 carriers was variable with a
mean age at onset of 62 years. However, 75% of the TBK1
carriers developed the disease after the age of 62, with two
mutation carriers still unaffected at an age above 80. The
latter carriers are members of Family DR158, in which the
Figure 4 Genotype–phenotype correlations in FTD patients. In these graphs, FTD patients are divided in groups based on their causal
gene mutation, i.e. TBK1, C9orf72 and GRN carriers and non-mutation carriers. The latter group is further divided by familial history in familial and
sporadic, and patients with unknown familial history. (A) Ages at onset. The boxplots illustrate the distribution of ages at onset in each FTD
patient group. For each genetic subtype a boxplot is created in which the middle horizontal line represents the median age at onset. The upper
and lower border of the box represent the value of the first quartile (25%) and the third quartile (75%) of the data. The whiskers represent the
minimal and maximal age at onset with exception of the outliers. The outliers are presented as circles and refer to ages at onset that are greater
than 1.5 interquartile ranges away from the 25th or the 75th percentile. (B) Subtype of behavioural FTD. This bar graph illustrates which
proportion of the behavioural variant FTD patients of each patient group has frontal disinhibition or apathy as predominant feature, respectively.
(C) Presence of extrapyramidal symptoms. In this bar graph, the proportion of patients who exhibit extrapyramidal symptoms are pictured for
each patient group. (D) Psychiatric symptoms. This bar graph shows the proportion of FTD patients with psychiatric symptoms for each patient
group. The bars are subdivided for the proportion of the major psychiatric characteristic.
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TBK1 p.Glu643del mutation co-segregated with disease
(Gijselinck et al., 2015a). This family has a high load of
patients with psychiatric symptoms that may have compli-
cated the diagnosis of FTD. Consequently, it is not
excluded that early symptoms of FTD might have been
wrongly interpreted in some carriers as psychiatric disease
symptoms, or vice versa. However, our data suggest that
the clinical penetrance of TBK1 loss of function mutations
might be incomplete as three carriers had no documented
familial history of neurodegenerative disease and only 50%
of the TBK1 carriers from our cohort of index patients and
relatives were affected by the age of 70.
The TBK1 carriers with FTD developed the ﬁrst symp-
toms signiﬁcantly later than C9orf72 carriers with FTD.
However, this ﬁnding should be cautiously interpreted as
the p.Glu643del mutation was over-represented among the
TBK1 carriers. Carriers of this speciﬁc mutation exhibited a
milder phenotype with signiﬁcantly later onset age
(66.3  3.9 years) and longer disease duration (8.3  1.8
years) than carriers of another TBK1 mutation (Gijselinck
et al., 2015a). Two p.Glu643del carriers with ALS were
siblings in Family DR663 and had remarkably young
onset ages (Patient II.1, 51 years and Patient II.2, 41
years; Fig. 1). These two ALS patients had also inherited
a C9orf72 expansion mutation as did a third sibling
(Patient II.4) who only carried the C9orf72 repeat expan-
sion and was still unaffected at the age of 62 (Gijselinck
et al., 2015a). This observation seems to support an inter-
action between the TBK1 and C9orf72 genes in patients
carrying a mutation in both genes, lowering onset age
(Cady et al., 2015). Another ALS carrier of p.Glu643del,
Patient DR1044, (Table 1), carried a ‘short’ C9orf72 ex-
pansion of 59 repeats units and had a disease onset at 63
years. We showed that C9orf72 carriers of a short repeat
expansion (range 45 to 80 repeat units), had a signiﬁcantly
later age at onset than those with long repeats (Gijselinck
et al., 2015b).
The disease duration of TBK1 carriers is relatively long,
particularly in patients with FTD (8.2  4.9 years). Though
not signiﬁcant, the disease duration was much shorter in
TBK1 carriers with ALS. These observations were in line
with earlier observations in C9orf72 carriers with ALS
(Cruts et al., 2013).
The majority of patients with FTD with a TBK1 muta-
tion were diagnosed with the behavioural variant of FTD.
We found a comparable fraction of behavioural variant
FTD in TBK1 carriers as in C9orf72 carriers, the latter
known to present most often with behavioural variant
FTD (Van Langenhove et al., 2013; Cooper-Knock et al.,
2014). Similar to these C9orf72 carriers, behavioural disin-
hibition and social inappropriate behaviour was more fre-
quent than apathy in TBK1 carriers. This is in contrast
with GRN carriers who more often presented with the lan-
guage variant, mostly with progressive non-ﬂuent aphasia
(Cruts et al., 2006; Cruts and Van Broeckhoven, 2008;
Gijselinck et al., 2008), and in case of behavioural variant
FTD, with apathy as the dominant feature (Beck et al.,
2008).
Psychiatric symptoms were present in450% of the
TBK1 carriers. However, as six of the seven TBK1 carriers
with psychiatric symptoms belonged to the same Family
DR158, we cannot draw ﬁrm conclusions regarding overall
occurrence of psychiatric symptoms in TBK1 carriers. As
only ﬁve TBK1 carriers with FTD were index patients, the
non-signiﬁcant result of the comparison with other muta-
tion carriers only taking into account index patients is not
sufﬁcient to reject the hypothesis that TBK1 carriers pre-
sent more frequently with psychiatric symptoms. Therefore,
research in larger cohorts of unrelated TBK1 carriers will
be needed.
Interestingly, memory loss and disorientation in time and/
or space were common early in the disease course of TBK1
carriers with FTD. Therefore, technical investigations were
more often necessary to allow a clear differentiation be-
tween FTD and Alzheimer’s disease. In Patient III.2 of
Family DR158 (Table 3), doubt persisted in the clinical
diagnosis between the frontal variant of Alzheimer’s disease
or FTD. This is in line with the observations by Pottier
et al. (2015), who described a TBK1 mutation in four pa-
tients with pathological diagnosis of FTLD or FTLD-MND
of which two had a clinical diagnosis of Alzheimer’s dis-
ease. Together, these observations suggest that screening of
clinically diagnosed Alzheimer’s disease patients for muta-
tions in TBK1 might be advisable. In Patient DR1124
(Table 1), who clinically presented with cognitive deﬁcits
and subsequently developed a rapidly evolving ALS pheno-
type, at autopsy we observed TDP-43 proteinopathy in the
motor neurons while hyperphosphorylated tau pathology
was present in the hippocampus (Fig. 4) in the absence of
other proteinopathies. The question remains whether this
hippocampal tauopathy might explain the cognitive decline
in the patient, or whether it is merely a sign of ageing
associated tauopathy. Three TBK1 carriers with ALS ex-
hibited prominent upper motor neuron signs and in two of
them no obvious electrophysiological evidence of lower
motor neuron disease was present upon disease presenta-
tion. However, neuropathological examination in Patient
DR1124 showed that TDP-43 and p62 positive neuronal
cytoplasmic inclusions were mainly restricted to the lower
motor neurons. Only one of the TBK1 carriers was diag-
nosed with FTD-ALS, preventing a genotype–phenotype
comparison with FTD-ALS patients carrying a C9orf72 ex-
pansion mutation. ALS occurred in the current study in
23.1% of the C9orf72 carriers in the Belgian FTD
cohort, a similar result as the previous observation of
27% by Van Langenhove et al. (2013). In the same FTD
cohort, none of the GRN carriers had ALS. TBK1 carriers
with FTD presented signiﬁcantly more often with extrapyr-
amidal symptoms than C9orf72 carriers and, when only
taking into account index patients, than GRN carriers.
Noticeably, all TBK1 carriers with extrapyramidal symp-
toms were carriers of the p.Glu643del mutation.
Parkinsonism is said to occur in 20–30% of FTD patients
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(Park and Chung, 2013), particularly linked to MAPT and
GRN mutations (Hutton et al., 1998; Baker et al., 2006;
Boeve and Hutton, 2008). Future studies in larger cohorts
of carriers of different TBK1 mutations are needed to
examine whether the association with extrapyramidal
symptoms holds true.
Structural neuroimaging in TBK1 carriers showed vari-
ous patterns of cortical atrophy, which could be global or
localized with frontotemporal predominance but also with
involvement of the parietal regions, the hippocampus or the
cerebellum. These variable ﬁndings are reminiscent of ﬁnd-
ings in C9orf72 carriers who exhibited widespread patterns
of atrophy with predominant atrophy of the frontal and, to
a lesser extent, of the anterior temporal lobes, without re-
gional speciﬁcity, and with involvement of the parietal
lobes and the cerebellum (Whitwell et al., 2012). In con-
trast with the generally symmetric pattern of atrophy in
C9orf72 carriers (Boeve et al., 2012; Mahoney et al.,
2012), more than half of our TBK1 carriers displayed an
asymmetric pattern of atrophy (most frequently with right
predominance). The variable widespread patterns are in
contrast with the more characteristic patterns observed in
GRN carriers who have most prominent atrophy in the
temporal and parietal lobes (Whitwell et al., 2009a;
Rohrer et al., 2010) or in MAPT carriers who present
with most prominent atrophy in the anteromedial temporal
lobes (Whitwell et al., 2009b; Rohrer et al., 2010). As in
C9orf72 carriers and GRN carriers, neuropathology of
TBK1 carriers is characterized by TDP-43 pathology.
Neuropathological examination had been carried out in
one FTD and one ALS patient and was compatible with
TDP-43 type B proteinopathy, as was reported in other
studies (Freischmidt et al., 2015; Pottier et al., 2015).
One study also reported TDP-43 type A in TBK1 carriers
with FTD (Pottier et al., 2015).
Our study has some limitations, as we identiﬁed in the
Belgian patients a relatively low number of TBK1 carriers
and also lacked detailed clinical information on three of the
carriers with ALS. Consequently, our observations in the
genotype–phenotype comparisons with C9orf72 carriers,
GRN carriers and non-mutation carriers were often not
or borderline signiﬁcant and need to be examined in
larger groups of TBK1 carriers. Also, not all TBK1 carriers
received the same investigations, since this study was lar-
gely performed retrospectively. The fact that six TBK1 car-
riers were members of the same family might have
inﬂuenced some of our results, such as the high load of
psychiatric symptoms, which might be due to other genetic
factors shared among relatives.
In conclusion, carriers of a TBK1 loss of function muta-
tion have a variable, but on average late onset age (58.1
years in ALS patients and 63.3 years in FTD patients).
Most patients with FTD present with behavioural variant
FTD, with disinhibition as the most prominent feature.
Memory loss is remarkably present in the initial phase of
the disease. Extrapyramidal symptoms occur rather often,
especially in carriers of the p.Glu643del mutation. On
neuroimaging, various patterns of atrophy as well as of
hypoperfusion or hypometabolism can be seen.
Neuropathologically, TBK1 carriers are characterized by
TDP-43 pathology. Based on the observed genotype–
phenotype correlations and the frequency of causal muta-
tions in C9orf72, GRN and TBK1 in our Belgian cohort,
we propose the following guidelines for the genetic diag-
nostic setting. After a negative result for the C9orf72 repeat
expansion, which still remains the major cause for FTD-
ALS and behavioural variant FTD, patients with FTD-ALS
or behavioural variant FTD should preferably be tested ﬁrst
for loss of function mutations in TBK1, speciﬁcally in FTD
patients with early memory difﬁculties in combination with
behavioural problems. Furthermore, in patients with a rela-
tively late onset age or in patients who present with extra-
pyramidal symptoms, TBK1 loss of function mutations,
especially the TBK1 mutation p.Glu643del, should be
considered.
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